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http://dx.doi.org/10.1016/j.ccr.2012.08.007SUMMARYBortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly
diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit
its long-term utility. Here, we show that P5091 is an inhibitor of deubiquitylating enzymeUSP7, which induces
apoptosis in MM cells resistant to conventional and bortezomib therapies. Biochemical and genetic studies
show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity. In animal tumor model studies,
P5091 is well tolerated, inhibits tumor growth, and prolongs survival. Combining P5091 with lenalidomide,
HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity. Our preclinical study there-
fore supports clinical evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.INTRODUCTION
Normal cellular homeostasis is maintained by a balanced regula-
tion of protein synthesis and degradation. The ubiquitin pro-
teasome system (UPS) is a nonlysosomal intracellular protein
degradation pathway mediated via proteasome holoenzyme,
ubiquitin ligases, and deubiquitylating (DUB) enzymes (Hershko,
2005). Specifically, the covalent attachment of ubiquitin to target
substrates leads to protein degradation via the multicatalytic
26S proteasome complex (Adams, 2004; Ciechanover, 2005);
conversely, the ubiquitylation process can be reversed bySignificance
Deregulation of the ubiquitin-proteasome system (UPS) is lin
cancer. Targeting the proteasome has proven to be a succ
research efforts led to the discovery of newer agents that targe
jugation rather than the proteasome itself, with the goal of gen
we utilized both in vitro and in vivo MM xenograft models to s
uitin-specific protease-7 (USP7) P5091. Our preclinical data sh
framework for clinical evaluation of USP7 inhibitors to improv
CanDUBs, which specifically cleave the isopeptide bond at the C
terminus of Ub (Nicholson et al., 2008). Deregulation of the
UPS pathway is linked to the pathogenesis of various human
diseases (Adams, 2004; Hoeller et al., 2006); therefore, inhibitors
of the UPS pathways, either at the level of proteasome, ubiquity-
lating, or DUB enzymes offers great promise as a novel thera-
peutic strategy.
Indeed, preclinical and clinical studies provided the basis for
FDA approval of the first-in-class proteasome inhibitor bortezo-
mib for treatment of multiple myeloma (MM) (Richardson et al.,
2003). Even though bortezomib therapy is a major advance, itked to pathogenesis of various human diseases, including
essful therapy in multiple myeloma (MM) patients. Recent
t enzymes modulating protein ubiquitin-conjugation/decon-
erating more specific and less toxic antitumor agents. Here,
how antitumor efficacy of a small molecule inhibitor of ubiq-
owing efficacy of P5091 in MM disease models provides the
e patient outcome in MM.
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USP7: A Therapeutic Target in MMhas been associated with possible off-target toxicities and the
development of drug-resistance (Lonial et al., 2005). More recent
efforts have focused on the discovery and development of small
molecule inhibitors of other major components of UPS, including
inhibitors of DUBs, E1-conjugating enzyme, or E3 ubiquitin
ligase. Among these, DUBs have emerged as a potential thera-
peutic target, given their role in several human diseases (Nichol-
son et al., 2007).
USP7 regulates key biological signaling pathways in tumori-
genesis (Everett et al., 1997; Hu et al., 2002; Li et al., 2002;
Nicholson et al., 2007), and its overexpression in prostate cancer
correlates with tumor aggressiveness (Song et al., 2008).MDM2,
a murine double minute oncogene (human ortholog HDM2), is
a primary substrate of USP7 and negatively regulates the tumor
suppressor protein p53 (Cummins et al., 2004; Li et al., 2004).
MDM2 ubiquitylates p53 and targets it for proteasome-mediated
degradation. Under normal conditions USP7 stabilizes MDM2
levels, which consequently drives p53 ubiquitylation and sub-
sequent degradation. Although MDM2 has autoubiquitylase
activity (Fang et al., 2000; Stommel and Wahl, 2004) and a
short half-life, which can be abrogated by USP7, a more recent
in vivo knockin model of inactive MDM2 showed that it is still
efficiently ubiquitylated through self-ubiquitylation-independent
mechanisms (Itahana et al., 2007). Genetic ablation of USP7
using siRNA or somatic knockout (KO) prevents USP7 from
deubiquitylating MDM2, resulting in stabilization of p53 (Cum-
mins et al., 2004; Kon et al., 2010; Li et al., 2004; Meulmeester
et al., 2005). Furthermore, p53 protein levels were elevated
in USP7/embryos, and the embryonic lethality of USP7/
mice was delayed in a p53/ background (Kon et al., 2010).
The functional consequences of inhibiting USP7 therefore in-
clude decreased HDM2 levels with accumulation of p53, induc-
tion of growth arrest via p21, and cell death. Mutations or
deletions of p53 are late events in MM, and activation of p53
may offer a novel therapeutic strategy (Anderson, 2007). USP7
also deubiquitylates other cancer targets (PTEN, FOXO4, or
claspin) and plays a role in DNA replication, apoptosis, and
endosomal organization (Nicholson et al., 2007). Therapeutic
strategies using USP7 inhibitors allow for specific targeting of
the UPS and are therefore less likely to trigger off-target activities
and associated toxicities.
Here, we demonstrate the efficacy of a small molecule inhib-
itor of USP7 P5091 in MM using both in vitro and in vivo models.
These findings provide the proof-of-concept for evaluation of
USP7 inhibitors as anti-MM agents.
RESULTS AND DISCUSSION
P5091 Is a Selective Inhibitor of USP7
P5091 is a trisubstituted thiophene with dichlorophenylthio,
nitro, and acetyl substituents mediating anti-USP7 activity (Fig-
ure 1A). P5091 was discovered using a ubiquitin-phospholipase
A2 enzyme (Ub-PLA2) reporter assay (Figure 1B) in a high-
throughput screening for inhibitors of USP7 from a diversity-
based library of small molecules. The structure-activity relation-
ship (SAR) data for selected analogs of P5091 is shown in
Figure 1C. Comparison of the halogen substituents of the 5-aryl-
sulfanyl moiety of the 2-acetyl-4-nitro-5-arylsulfanylthiophenes
demonstrated that the unsubstituted phenyl analog 1 was not346 Cancer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier Inactive as a USP7 antagonist, whereas all of the 5- mono and
dihalo phenylsulfanylthiophenes, including P5091 (5), exhibited
USP7 inhibitory activity. In addition, the dichloro analogs (5–7)
and difluoro analog were more potent than the monochloro
analogs (2–4). Initial exploration of the R2 position (9–12) did
not result in enhanced potency. Importantly, P5091 (Compound
5; Figure 1C) exhibited potent, specific, and selective deubiqui-
tylating activity against USP7 (EC50 = 4.2 ± 0.9 mM). In contrast,
P5091 did not inhibit other DUBs or other families of cysteine
proteases tested (EC50 > 100 mM) (Figure 1D). P22074, an inac-
tive analog of P5091, served as a negative control (Figure 1D).
To determine the USP7 inhibitory activity of P5091 in living
cells, we performed competition assays between P5091 and
the ubiquitin (Ub) active site probe Ub-vinyl methyl ester (HA-
UbVME) (Borodovsky et al., 2002). P5091 inhibited the labeling
of USP7 with HA-UbVME in a concentration-dependent manner
(Figure 1E). Untreated cell lysates incubated with Ub-probes
exhibited Ub-USP7 conjugate formation, as reflected by the
increase in mass of USP7 of 10 kDa. In contrast, Ub-USP7
conjugate formation was inhibited in cell lysates from P5091-
treated cells at concentrations as low as 5–10 mM P5091, with
a concomitant increase in the unlabeled free form of USP7. No
gross difference in the labeling of other DUBs with Ub-VME
was observed, even at 40 mM. The residual active USP7 may
relate to the irreversibility-related potency of HA-Ub probe
versus P5091 and/or kinetics of labeling of HA-Ub probe against
USP7. P5091 treatment did not inhibit other DUBs, such as
USP5, UCHL1, or UCHL3 (Figure S1A available online). These
data demonstrate the P5091 activity against USP7 in the cellular
environment.
Isopeptidase activity analyses shows that USP7 efficiently
cleaves high molecular weight polyubiquitin chains (Ub7- and
K48-linked ubiquitin chains), and USP7-mediated cleavage
of these chains is inhibited in a dose-dependent manner by
P5091 (Figure 1F). Moreover, P5091 inhibits USP7- but not
USP2- or USP8-mediated cleavage of poly K48-linked ubiquitin
chains (visualized by the presence or absence of monoubiquitin)
(Figure S1B).
USP7 Knockout Renders Cells Resistant to P5091
To further determine whether the inhibitory effect of P5091 is
mediated via USP7, we utilized human cells (HCT116 USP7/)
in which the USP7 is disrupted by targeted homologous recom-
bination (Cummins et al., 2004). P5091 decreased the viability of
HCT116 (WT) cells in a time- and concentration-dependent
manner; conversely, a marked reduction in P5091 cytotoxic
activitywas observed againstHCT116USP7/ cells (Figure 1G).
HCT116 USP7/ cells are slow proliferating cells compared to
HCT116 (WT). To exclude the possibility that the differences
observed during P5091 treatment is not due to growth rate, cells
were serum starved and examined for P5091 effects. In agree-
ment with our results in Figure 1G, P5091 decreased the viability
of HCT116 (WT) cells, whereas cytotoxic activity of P5091 was
significantly blocked in USP7/ cells (Figure S1C). USP7/
mice die during early embryonic development (Kon et al.,
2010). The KO selection process in HCT116 USP7/ cells can
contribute to the development of a compensatory mechanism
for the loss of USP7 for survival. Nonetheless, our data using
HCT116 USP7/ cells suggests that P5091 targets USP7.c.
Figure 1. P5091 Is a Selective Inhibitor of
USP7 Activity
(A) Chemical structure of P5091.
(B) Schematic representation of Ub-PLA2 iso-
peptidase reporter assay: cleavage by the iso-
peptidase at the carboxy-terminal glycine of
the Ub releases catalytically active PLA2, which
liberate a quantifiable fluorescent product in the
presence of its substrate.
(C) Structure-activity relationship data for selected
analogs of P5091 (compound 1 = P22074 and
compound 5 = P5091).
(D) P5091 demonstrates potent and specific inhi-
bition of USP7 in vitro versus other DUBs and
proteases.
(E) HEK293T cells were treated with DMSO or
P5091; crude cell extracts were labeled with indi-
cated UbVME probe, followed by immunoblotting
(IB) with indicated antibodies.
(F) P5091 inhibits higher molecular weight poly-
ubiquitin chain cleavage in a dose-dependent
manner. NEM (N-ethyl maleimide) is a nonspecific
inhibitor of USP7 and served as control.
(G) HCT116 (WT) and HCT116 USP7/ cells were
treated with vehicle or indicated concentrations of
P5091 for 24, 48, and 72 hr and then analyzed for
viability using MTT assay (mean ± SD; n = 3). Error
bars indicate SD.
See also Figure S1.
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USP7: A Therapeutic Target in MMP5091 Targets USP7 Substrate HDM2
Genetic ablation of USP7 destabilizes its substrate, HDM2
(Cummins et al., 2004; Li et al., 2004). U20S cells were transiently
transfected with HA-Ub constructs, and endogenous HDM2
ubiquitylation was analyzed by pulling down ubiquitylated
proteins using Tandem Ubiquitin Binding Entities (TUBEs)
(Hjerpe et al., 2009). Empty-vector/vehicle served as a control
to determine the effects of HA-Ub alone on HDM2 ubiquiti-
nation (Figure 2A, lane 2, empty vector versus lane 3, HA-Ub).
HA-Ub transfection alone slightly increases HDM2-ubiq-
uitination versus empty-vector. Importantly, addition of P5091
markedly increases HDM2 ubiquitination, in particular, the
band between 130–170 (lane 3 versus lane 4). The band betweenCancer Cell 22, 345–358, Se130–170 kDa likely represents a pre-
dominantly multiubiquitylated form of
HDM2; a similar banding pattern has
been recently reported (Zhao et al.,
2011). The mock pulldown (lane 1) is
negative control for TUBE1 using uncon-
jugated Agarose. Alternatively, we asked
whether HDM2 stabilization is affected
in the presence of P5091. P5091 acceler-
ates the degradation of HDM2 versus
control cycloheximide (CHX) alone-
treated U20S cells (Figure 2B). Likewise,
P5091 enhanced the degradation of
HDM2 in prostate cancer cell lines (Fig-
ure S2). Together, our data suggest
that USP7 inhibition by P5091 induces
HDM2 polyubiquitylation and accelerates
degradation of HDM2.Prognostic relevance of USP7 in multiple myeloma protea-
some inhibition has proven to be a successful treatment strategy
for MM patients (Richardson et al., 2003). Because USP7 is also
a component of UPS, we examined the effects of USP7 inhibition
with P5091 in MM cells. Immunohistochemistry (IHC) studies
using bone marrow (BM) biopsies from MM patients and normal
healthy donors showed a significantly higherUSP7 expression in
MM cells than in normal cells (Figure 3A). Normal plasma cells
lack detectable USP7 expression. Similar results were observed
using protein extracts from MM patient tumor cells versus
normal cells, and MM cell lines (Figure 3B).
We retrospectively analyzed the prognostic significance of
baseline USP7 expression from BM biopsy samples on theptember 11, 2012 ª2012 Elsevier Inc. 347
Figure 2. Effect of P5091 on USP7 Substrate
HDM2
(A) U2OS cells were transfected with HA-Ub
(WT), and 48 hr posttransfection, cells were
treated with DMSO or P5091 (30 mM) for 4 hr.
Endogenous HDM2 ubiquitylation was analyzed
by pulling down ubiquitylated proteins using
TUBEs (Supplemental Experimental Procedures).
Cell lysates were normalized for HDM2 protein and
incubated with uncojugated Agarose or TUBE1
conjugated Agarose; samples were separated
by SDS-PAGE, and HDM2 ubiquitylation was
detected using anti-HDM2 antibody. Whole-cell
extracts (WCE) were subjected to IB using anti-
HDM2 and anti-actin antibodies.
(B) U2OS cells were pretreated with either vehicle
or P5091 (15 mM, IC50) for 2.0–3.5 hr, followed by
addition of CHX (40 mg/ml) for the indicated times.
Total proteins lysates were subjected to immuno-
blotting with anti-HDM2 or anti-actin antibodies.
Densitometry was utilized to quantify HDM2 pro-
tein levels after normalization with actin control
to obtain percent HDM2 degradation (mean ± SD;
n = 3).
Error bars indicate SD. See also Figure S2.
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USP7: A Therapeutic Target in MMoverall survival and event-free survival of 170 MM patients
enrolled in a clinical trial. Results show a statistically significant
inverse correlation between USP7 levels and overall survival
(Figure 3C). Additionally, MM patients with lower USP7 levels
survived for longer timespan with no recurrence of the disease
following therapy (Figure 3D). Together, these data suggest
a role of USP7 in the pathogenesis of MM and provide a rationale
for targeting USP7 in MM.
P5091 Inhibits USP7 Deubiquitylating Activity, without
Blocking Proteasome Activity, in MM Cells
P5091 causes significant inhibition (>50%) of USP7 activity in
a concentration-dependent manner (Figure 4A). Although borte-
zomib blocks chymotrypsin-like (CT-L) proteasome activity, no
significant inhibition of CT-L activity was observed in P5091-
treated MM cells (Figure 4B). P5091 (25–50 mM) had no effect
on trypsin-like (T-L)- or caspase-like (C-L) proteasome activities
(Figure S3A). A comparative analysis shows that bortezomib
induced a marked increase in ubiquitylated proteins (Figure 4B),
whereas a modest increase in polyubiquitylation was observed
in P5091-treated cells. This is likely due to the narrow USP7
substrate activity compared to bortezomib, which has a broader
substrate spectrum. These data suggest that P5091 blocks
USP7 activity without altering proteasome function.
P5091 Inhibits Growth in MM Cells and Overcomes
Bortezomib-Resistance
P5091 induces a dose-dependent decrease in viability of various
MM cell lines, including those that are resistant to conventional
therapies dexamethasone (Dex) (MM.1R), doxorubicin (Dox-
40), or melphalan (LR5) (IC50 range 6–14 mM) (Figure 4C).
P5091 blocks the USP7 activity in MM at the IC50 of P5091 for
these cells (Figure 4A and data not shown). In contrast,
P22074 had no significant effect on the viability. The variable
IC50 of P5091 against MM cell lines may be due to their dis-
tinct genetic background and/or drug-resistance characteristics348 Cancer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier In(Anderson, 2007). USP7-siRNA inhibited cell proliferation; con-
versely, transfection of USP7 (WT) rescued cells from the
growth-inhibitory effects of USP7-siRNA (Figure 4D). Immuno-
blot analysis shows a significant knockdown of USP7 by
USP7-siRNA versus scrambled (scr)-siRNA, and restoration of
USP7 levels in cells transfected with USP7 (WT) versus USP7-
siRNA (Figure 4D, inset).
To determine whether P5091 similarly affects purified patient
MM cells, tumor cells from eight MM patients, including those
relapsing after multiple prior therapies, such as bortezomib,
lenalidomide, and Dex, were treated with P5091. Patient MM
was deemed to be refractory to bortezomib therapy when
progressive disease occurred in spite of bortezomib treatment;
in addition, most bortezomib-resistant MM was refractory to
lenalidomide and Dex therapies as well. A dose-dependent
decrease in the viability of all patient MM cells was noted after
P5091 treatment (Figure 4E). We next examined whether tumor
cells from bortezomib-resistant MMpatients are affected by bor-
tezomib treatment in vitro and whether P5091 exerts a cytotoxic
effect in these cells (Figure 4F). Results demonstrate a varying
sensitivity to bortezomib in vitro (10%–50%decrease in viability),
albeit at much higher concentrations (12.5 nM) than normally
observed IC50 for MM cells (3–5 nM) in three of six samples;
however, all patient cells were significantly more sensitive to
P5091 (IC50 % 3 mM). These findings show the ability of P5091
to trigger cytotoxicity, even in patient tumor cells resistant to
bortezomib, Dex, or lenalidomide therapies.
To further address this issue, we utilized bortezomib-sensitive
(ANBL-6.WT) and bortezomib-resistant (ANBL-6.BR) isogenic
MM cell lines. Cell viability analysis showed that the IC50 of drugs
for ANBL-6.WT or ANBL-6.BR were 2.32 nM and 12.05 nM for
bortezomib and 6.83 mM and 9.85 mM for P5091. As seen in Fig-
ure 4G, the IC50 ratio (ANBL-6.BR/ANBL-6.WT) of P5091 is
significantly less than bortezomib (p < 0.001), demonstrating
the ability of P5091 to overcome bortezomib resistance. Finally,
P5091 at the IC50 for MM cells does not significantly affect thec.
Figure 3. USP7 Expression and Prognostic Relevance in MM Cells
(A) IHC analysis of BM biopsies from normal donors and MM patients to show USP7 expression. Red arrowheads indicate USP7-positive cells (brown color).
Yellow arrowheads represent normal plasma cells; magenta arrowheads are neutrophils. Scale bars, 50 mm (10 mm in insets).
(B) Purified tumor cells fromMM patients, normal peripheral blood mononuclear cells (PBMCs), and MM cell lines were analyzed for USP7 expression level by IB
with anti-USP7 and anti-actin antibodies.
(C and D) Kaplan-Meier plots on prognostic relevance ofUSP7 expression on the overall and event-free survival for MM patients. The blue line indicates a patient
group with higherUSP7 expression and shorter survival, whereas the red line represents a group of patients with lowerUSP7 expression and longer survival. See
Web site (http://www.ncbi.nlm.nih.gov/geo/) for gene expression data under accession number GSE39754.
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USP7: A Therapeutic Target in MMviability of normal PBMCs (Figure 4H). Higher concentrations of
P5091 (25 mM) decrease the viability of PBMCs by 20%–25%,
suggesting that normal cells are not completely refractory to
P5091. These data show a favorable therapeutic index for
P5091 in MM.
P5091 Overcomes Bone Marrow Stromal Cell-Induced
Growth of MM Cells
Interaction of MM cells with BMSCs triggers cytokine secretion,
which mediates paracrine growth of MM cells and protects
against drug-induced apoptosis (Chauhan et al., 2005b). To
determine whether P5091 affects BMSCs-triggered MM cell
growth, MM.1S cells were cultured with or without BMSCs in
the presence or absence of various concentrations of P5091.
P5091 treatment inhibited BMSCs-induced proliferation of
MM.1S (Figure 4I). P5091 treatment does not affect the viability,
morphology, or function of BMSCs (Figures S3B–S3D). These
data suggest that P5091 not only directly targets MM cells but
also overcomes the cytoprotective effects of the MM-host BM
microenvironment.
We next examined whether anti-MM activity of P5091 is due to
apoptosis. P5091 treatment shows accumulation of cells in
early- (Ann V+/PI) and late-stage (Ann V+/PI+) apoptosis (Fig-
ure S3E), associated with proteolytic cleavage of poly (ADP)
ribose polymerase (PARP) (Figure S3F). Treatment of MM.1S
and RPMI-8226 cells with P5091 induces caspase-3 cleavageCanand activates caspase-9 and casapse-8 apoptotic pathways
(Figure S3F). Biochemical inhibition of either caspase-8 (IETD-
FMK) or pan-caspase inhibitor (Z-VAD-FMK)markedly abrogates
P5091-triggered cytotoxicity (Figure 4J). These findings sug-
gest that (1) P5091 triggers both mitochondria-dependent and
mitochondria-independent signaling pathways and (2) P5091-
induced apoptosis is mediated, at least in part, via caspases.
Effect of P5091 on HDM2/p53/p21 Pathway in MM Cells
In agreement with our results usingU20S cells (Figure 2A), P5091
increases ubiquitination of endogenous HDM2 in MM.1S cells
(Figure S4A). In contrast to U20S cells, higher levels of endoge-
nous poly-Ub HDM2 were observed in MM.1S cells in the
absence of exogenous Ub transfection. Importantly, a significant
increase in HDM2 ubiquitination was noted in P5091-treated
cells compared to untreated cells. Even though similar bands
are observed in DMSO-treated U2OS cells (Figure 2A, lanes 2
and 3) as well as in MM.1S cells (Figure S4A), P5091 treatment
resulted in accumulation of band between 130–170 kDa only in
U2OS cells (Figure 2A, lane 3), suggesting cell-type-specific
differences in HDM2 ubiquitination that is sensitive to P5091
treatment.
USP7 regulates HDM2, HDMX, and p53 pathways (Cummins
et al., 2004; Li et al., 2004). P5091 decreased HDM2 and
HDMX, as well as upregulated p53 and p21 levels (Figure 5A).
Pretreatment of MM.1S cells with P5091, followed by CHXcer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier Inc. 349
Figure 4. P5091 Inhibits USP7 Activity, Induces MM Cell Death, and Overcomes Bortezomib-Resistance
(A) MM.1S cells were treated with DMSO or with P5091 for 3 hr; cellular USP7 was immunoprecipitated under native conditions and analyzed for USP7 activity
using the Ub-EKL assay (p < 0.05; n = 2).
(B) MM.1S cells were treatedwith DMSOorwith P5091 or bortezomib for 3 hr; protein lysates were analyzed for proteasome activity. Raw datawere normalized to
percent proteasome activity in control (as 100%) versus drug-treated cells (mean ± SD; n = 3). Protein lysates from control, P5091-, or bortezomib-treatedMM.1S
cells were subjected to IB with anti-Ub antibody.
(C) MM cell lines were treated with DMSO or with P5091 for 48 hr, followed by assessment for cell viability (mean ± SD; p < 0.001 for all cell lines; n = 3).
(D) MM.1S cells were cotransfected with scr-siRNA plus empty-vector, USP7-siRNA plus empty-vector, or USP7-siRNA plus active USP7 (WT) and subjected to
growth analysis using CellTiter-Glo assay (mean ± SD; n = 3). Immunoblot shows USP7 expression in cells transfected with scr-siRNA plus empty-vector (lane 1),
USP7-siRNA plus empty-vector (lane 2), or USP7-siRNA plus active USP7 (WT) (lane 3) (Inset).
(E) Purified patient MM cells were treated with P5091 for 48 hr and analyzed for viability (mean ± SD of triplicate cultures; p < 0.001 for all patient samples).
(F) MM cells from six bortezomib-resistant patients (Pt. #1–#6) were treated in a side-by-side manner with either bortezomib or P5091 for 48 hr and analyzed for
viability (mean ± SD of triplicate cultures; p < 0.001 for all patient samples).
(G) Bortezomib-sensitive (ANBL-6.WT) and Bortezomib-resistant (ANBL-6.BR) cells were treated with either bortezomib or P5091 for 48 hr, followed by
assessment for cell viability. The bar graph shows the IC50 ratio (ANBL-6.BR/ANBL-6.WT) of P5091 and bortezomib (mean ± SD; n = 2).
(H) Normal PBMCs were treated with P5091 for 48 hr and analyzed for viability (mean ± SD of quadruplicate cultures).
(I) MM.1S cells were cultured with or without BMSCs for 72 hr, and DNA synthesis wasmeasured by 3H-TdR uptake (mean ± SD of triplicate cultures; p < 0.001 for
all samples).
(J) MM.1S cells were pretreated with inhibitors of caspase-8, caspase-9, or pan-caspase for 1 hr, and then P5091 (12.5 mM) or bortezomib (10 nM) was added for
another 24 hr, followed by analysis of viability.
Error bars (A–J) indicate SD. See also Figure S3.
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USP7: A Therapeutic Target in MMaddition resulted in the rapid degradation of HDM2 and in-
creased steady-state protein levels of p53 and p21 (Figure 5B).
This increase in p53 and p21 was not due to enhanced transcrip-
tion at the tested time point (Figure S4B). HDMX stability was
only slightly decreased in both control and P5091-treated cells,
likely because of its long half-life in human cancer cells (Li and350 Cancer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier InGu, 2011). The P5091-induced HDM2 degradation was blocked
in the presence of proteasome inhibitor MG132 (Figure S4C),
suggesting that HDM2 degradation is proteasome dependent.
We next examined the role of HDM2, p53, and p21 during
P5091-induced cytotoxicity using loss-of-function studies and
a KO cell system. HDM2-siRNA reduced HDM2 levels comparedc.
Figure 5. Mechanisms Mediating Anti-MM Activity of P5091
(A) MM.1S and RPMI-8226 cells were treated with P5091 (6.25 and 12.5 mM) for 24 hr; protein lysates were subjected to IB with anti-HDM2, anti-HDMX, anti-p53,
anti-p21, or anti-actin antibodies.
(B) MM.1S cells were pretreated with P5091 (6.25 mM) for 4 hr, followed by addition of CHX (50 mg) for the final 0–120 min of the experiment. Protein lysates were
subjected to IB using indicated antibodies.
(C) MM.1S cells were transfected with either scr- or HDM2-siRNA. After 24 hr of transfection, cells were treated with vehicle or indicated concentrations of P5091
for an additional 24 hr, followed by analysis of cell viability (mean ± SD; n = 3).
(D) p53/ and p53//MDM2/ MEFs were treated with P5091 for 48 hr, followed by analysis of cell viability (mean ± SD; n = 3).
(E) MM.1S cells were transfected with scr- or p53-siRNA, followed by treatment with P5091 or Nutlin-3A for 48 hr, and then analyzed for viability (mean ± SD;
n = 3).
(F) HCT116 p53 (WT) and HCT116 p53/ cells were treated with DMSO, P5091, or Nutlin-3A for 72 hr, followed by assessment for cell viability (mean ± SD; n = 3).
(G) ARP-1 MM cells were treated with DMSO or P5091 for 48 hr and analyzed for cell viability (mean ± SD; n = 3). Inset: Lysates from control and P5091-treated
ARP-1 cells were analyzed for HDM2 and p21 levels using IB.
(H) MM.1S cells were treated with DMSO or P5091 (6.25 mM) for 12 hr; cell lysates were immunoprecipitated with anti-p21, anti-HDM2, or corresponding isotype
control (mock) antibodies, and the immune complexes were then subjected to IB with anti-HDM2 and anti-p21 antibodies.
(I) MM.1S cells were transfected with scr- or p21-siRNA, followed by treatment with P5091 for 48 hr, and then analyzed for viability (mean ± SD; n = 3). Percent cell
viability was normalized (as 100%) for scr- or p21-siRNA controls, respectively.
(J) HCT116 (WT) and HCT116 p21/ cells were treated with DMSO or with P5091 for 48 hr, followed by assessment for cell viability (mean ± SD; p < 0.001; n = 3).
Error bars in (C–G), (I), and (J) indicate SD. See also Figure S4.
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fected cells with P5091 further modestly decreased HDM2 levels
(Figure S4D). It is likely that knocking down HDM2 alone nega-
tively impacts the HDM2/HDMX heterocomplex, as well as over-Canall HDM2 E3 ligase activity and polyubiquitylation status of
HDM2, thereby resulting in the remaining HDM2 (in HDM2-siRNA
cells) being comparatively less sensitive to the effects of P5091.
As seen in Figure S4E, which shows absolute levels of viablecer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier Inc. 351
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63.66% (0.322/0.5063 100%) normalized to scr-siRNA control.
Further derivation from absolute values (Figure S4E) show that
the percentage of viable cells in scr- and HDM2-siRNA-trans-
fected cells upon treatment with P5091 (6.25 and 12.5 mM)
was 47.2%, 8.6%, and 73.3% and 19.2%, respectively (Fig-
ure 5C). In concert with these data, P5091 downregulated
HDM2 and HDMX, as well as upregulating p53 and p21 levels,
in scr-siRNA-transfected cells (Figure S4D). p53 levels were
slightly increased by HDM2-siRNA knockdown and further upre-
gulated by P5091 treatment. HDM2-siRNA, like P5091 alone,
upregulated p21 levels, which remained unaffected by the
combination of HDM2-siRNA and P5091. The role of HDM2
during P5091-induced cell death was further examined using
p53/ and p53//MDM2/ (double KO) mouse embroyonic
fibroblasts (MEFs). Results demonstrate significantly reduced
cytotoxicity of P5091 in p53//MDM2/ cells versus p53/
MEFs (IC50 of P5091 for p53
/: 7.72 mM and for p53//
MDM2/: 20.88 mM) (Figure 5D). Together, these data suggest
that (1) the effects of HDM2-siRNA alone may not absolutely
mimic the responses triggered by P5091 and (2) P5091-induced
cytotoxicity is mediated in part via HDM2.
Interestingly, p53 depletion by siRNA does not affect the
P5091-induced decrease in MM.1S cell viability (Figure 5E). In
contrast, p53 depletion inhibited cytotoxic effects of Nutlin-3A
(Figure 5F), an MDM2-p53 interaction antagonist, suggesting
its dependence of p53. We further utilized two different strate-
gies to further address this issue: first, we used HCT116 p53
(WT) and HCT116 p53/ cells to show that P5091, but not
Nutlin-3A, exerts equipotent cytotoxicity in both cell types (Fig-
ure 5F). Second, P5091 treatment decreases the viability of
p53 null ARP-1 MM cells (Figure 5G), associated with decreased
HDM2 levels and increased p21 expression (Figure 5G, inset).
Together, these data suggest that although P5091 increase
p53 levels (Figure 5A), its cytotoxic activity is not dependent on
p53. A recent report also highlighted a p53-dependent and
p53-independent function of USP7 (Kon et al., 2011). Our find-
ings have important clinical implications because 10%–15% of
MM patients have p53 mutations/deletions, which confer drug
resistance; a therapeutic approach using USP7 inhibition would
allow for potent anti-MM activity, even in this patient population.
Our data show that besides p53, P5091 treatment also upre-
gulates p21, a known downstream target of HDM2-p53 axis
(Enge et al., 2009; Vogelstein et al., 2000; Xu et al., 2010).
MDM2 inhibition is associated with induction of p21 in human
cancer cells regardless of p53 status, suggesting a role of
MDM2 in p21 regulation as well as p21 function in mediating
p53-independent apoptosis (Wang et al., 2001, 2002; Wu
et al., 2002; Zhang et al., 2003, 2004). We examined the effect
of P5091 on HDM2-p21 signaling axis. Coimmunoprecipitation
assays show that HDM2 is associated with p21 in MM cells
and that P5091 downregualates HDM2 and upregualtes p21
(Figure 5H). Silencing of p21 with siRNA attenuates P5091-
induced cytotoxicity (Figure 5I). Similarly, treatment of HCT116
p21/ cells significantly blocked P5091-triggered cytotoxicity,
associated with late-stage apoptosis (Figures 5J and S4F). The
P5091-induced increase in p21 protein is in concert with an
earlier study showing that MDM2 negatively regulates p21 pro-
tein by directly binding to it and facilitating its proteasomal352 Cancer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier Indegradation (Zhang et al., 2004). Although P5091 upregulates
and stabilizes p21 in MM cells, it triggers a modest accumulation
of endogenous ubiquitylated p21 (Figure S4G). The mecha-
nism(s) underlying the USP7-inhibition-mediated p21 ubiquityla-
tion and stabilization in MM cells remains to be defined. None-
theless, previous reports showed that p21 ubiquitylation is not
a prerequisite for proteasomal degradation and that the p21
ubiquitylation may serve some function other than proteasome
degradation via conformation changes (Sheaff et al., 2000;
Zhang et al., 2004; Xu et al., 2010).
Overall, our mechanistic studies show that (1) P5091-induced
cytotoxicity is mediated in part via HDM2-p21 signaling axis and
(2) although p53 is upregulated in response to P5091 treatment,
the cytotoxic activity of P5091 is not dependent on p53. It is
possible that other signaling molecules besides HDM2 or p21
contribute to the overall response to P5091 because HDMX is
also the downstream target of USP7 and recent studies showed
interaction of USP7 with Claspin, PTEN, or FOXO4.
P5091 Inhibits Human MM Cell Growth In Vivo and
Prolongs Survival in the MM.1S MM Xenograft Mouse
Model
We next examined the in vivo efficacy of P5091 using human
plasmacytoma xenograft and SCID-hu mouse models (Chau-
han et al., 2005a). These two distinct models have been
immensely useful in extensively validating novel anti-MM thera-
pies bortezomib and lenalidomide, leading to their translation to
clinical trials and FDA approval for the treatment of MM. Treat-
ment of MM.1S tumor-bearing mice with intravenous (IV) injec-
tion of P5091 inhibits MM tumor growth and prolongs survival of
these mice (Figures 6A and 6B). Examination of harvested
tumors showed that P5091 inhibited USP7 activity, decreased
HDM2, and increased p21 levels relative to tumors from control
mice (Figure 6C). P5091 decreases proliferation in harvested
tumors, as assessed by BrdU and Ki67 staining (Figures 6D
and S5A). P5091 increases the number of cleaved-caspase-3-
and TUNEL-positive apoptotic tumor cells versus vehicle treat-
ment (Figures 6E and S5B). P5091 was well tolerated, since no
significant weight loss in mice was observed (Figure S5C).
These data show potent in vivo apoptotic activity of P5091
against MM cells.
P5091 Triggers Antiangiogenic Activity In Vivo
MM cell growth is associated with angiogenesis, and vascular
endothelial growth factor (VEGF) plays a role in this process (An-
derson, 2007). To determine whether P5091 triggers antiangio-
genic activity, we evaluated tumors harvested from mice by im-
munostaining using distinct markers of angiogenesis, VEGFR2,
and platelet endothelial cell adhesion molecule (PECAM1).
P5091 decreases the number of VEGFR2- and PECAM1-positive
cells (Figures 6Fa and 6Fb). Tumor sections were also analyzed
for expression of LYVE1 (lymphatic vessel marker), ENG (endo-
glin/CD105), and ACTA2/a-SMA (smooth muscle cell marker).
A marked decrease in the number of LYVE1- and ENG-positive
cells is observed in tumors from P5091-treated mice versus
control mice (Figures 6Fc and 6Fd), suggesting that P5091 expo-
sure results in reduction of tumor vasculature. Dual immuno-
staining of harvested tumors with PECAM1 and ACTA2 confirms
the disappearance of intact larger vessels in P5091-treatedc.
Figure 6. P5091 Inhibits Xenografted Human MM Cell Growth, Prolongs Survival, and Blocks Angiogenesis in CB-17 Mice
(A) Mice bearing humanMM.1SMM tumors were treated with vehicle or P5091 (10mg/kg; IV) twice weekly for 3 consecutive weeks. Data are presented as mean
tumor volume ± SD (ten mice/group).
(B) Kaplan-Meier survival plot shows survival of mice.
(C) Tumors from vehicle or P5091-treatedmice were analyzed for USP7 activity. Inset: Immunoblot shows equal USP7 protein input. HDM2 and p21 levels inmice
tumors were analyzed by IB. Tumor sections from control and P5091-treated mice were immunostained with anti-HDM2 antibody and DAPI. Scale bars, 50 mm.
(D) Tumor sections from control and P5091-treated mice were immunostained with BrdU and Ki67 antibodies. Nuclear staining was performed with DAPI. White
rectangle in the middle control panel represents the 53 enlarged area. White scale bars, 50 mm. Yellow scale bars, 10 mm.
(E) Apoptotic cells in tumors sectioned from control or P5091-treated mice were identified by immunostaining for activated caspase-3 (red cells), TUNEL (green
cells), and DAPI (blue). White rectangle represents 53 enlarged area. Black arrowheads point at apoptotic cells. Scale bars, 50 mm (10 mm in the inset).
(F) Tumor sections from control and P5091-treated mice were subjected to immunostaining with anti-PECAM1, anti-VEGFR2, anti-LYVE1, or anti-ENG anti-
bodies. Nuclear staining was performed with DAPI. Scale bars, 50 mm.
(G) Tumor sections from control and P5091-treated mice were subjected to dual immunostaining with PECAM1 and ACTA2. White rectangle represents 53
enlarged area. Scale bars, 50 mm.
(H) Quantification of ACTA2-positive cells shown in (G). *p < 0.05.
Error bars represent SD. See also Figure S5.
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inhibits tumor-associated angiogenic activity.
Characterization of P5091 Efficacy in Distinct Animal
Models
Because our in vitro data showed that P5091 triggers apoptosis
in p53 null ARP-1 MM cells, we evaluated whether P5091 simi-
larly affects the growth of ARP-1 cells in vivo. Treatment of
ARP-1 tumor-bearingmicewith P5091 inhibitsMM tumor growth
and prolongs survival of these mice (Figures 7A and 7B). Impor-
tantly, a marked inhibition of USP7 activity was noted in tumors
from P5091-treated mice compared with tumors from controlCanmice (Figure 7C). Although P5091 targets USP7, as tested using
a panel of DUBs, we cannot rule out the possibility of involve-
ment of yet unknown DUB, other molecules of similar homology,
or other USP7 substrates in mediating biological responses.
Nonetheless, our data show an early inhibition (at 3 hr) of USP7
activity in vivo in response to P5091 treatment. Blood chemistry
profile of P5091-treated mice showed normal levels of bilirubin,
hemoglobin, and creatinine (Figure S6A), suggesting that P5091
treatment was well tolerated.
We next compared the in vivo efficacy of P5091 with borte-
zomib. A head-to-head analysis of P5091 versus bortezomib
at their MTD doses showed a similar tumor growth inhibitioncer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier Inc. 353
Figure 7. P5091 Targets USP7 In Vivo and Exhibits Antitumor Activity in Distinct Animal Models
(A)Mice bearing human p53 null ARP-1MM tumorswere treatedwith either P5091 (10mg/kg; IV) or vehicle control twiceweekly for 3 consecutive weeks. Average
and standard deviation of tumor volume (mm3) is shown from mice versus time when tumor was measured (mean tumor volume ± SD, six mice/group).
(B) Kaplan-Meier plot shows survival in mice.
(C) Tumors from vehicle or P5091-treated mice were analyzed for USP7 activity. Immunoblot shows that equal USP7 protein input.
(D) Average and standard deviation of tumor volume (mm3) is shown from mice (n = 5/group) versus time when tumor was measured. RPMI-8226 cells (53 106
cells/mouse) were implanted in the rear flank of female mice. On day 28–30, mice were randomized to treatment with vehicle, MTD doses of P5091 (20mg/kg), or
with bortezomib (1 mg/kg) on a twice-weekly schedule for 3 weeks.
(E) SCID-hu mice bearing INA-6 MM tumors (five mice/group) were treated with either vehicle alone or P5091 (10 mg/kg), and mouse serum samples were
analyzed for shIL-6R.
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and S6B).
Because MM-host BM microenvironment confers growth,
survival, and drug resistance in MM cells (Anderson, 2007), we
examined whether the anti-MM activity of P5091 is retained in
the presence of human BM microenvironment. For these
studies, we utilized the SCID-hu model (Anderson, 2007), which
recapitulates the human BM milieu in vivo. In this model, INA-6
MM cells are injected directly into human bone chips implanted
subcutaneously in SCID mice, and MM cell growth is assessed
by serial measurements of circulating levels of soluble human
interleukin 6-receptor (shIL-6R) in mouse serum. P5091 treat-
ment inhibited tumor growth in these mice (Figure 7E), suggest-
ing that P5091 can trigger anti-MM activity, even in the presence
of the human BM milieu. Finally, in order to determine whether
P5091 induces antitumor activity in other cancer cell types, we
utilized a human leukemic lymphoblast (CCRF-CEM) xenograft
model. Treatment of tumor-bearing mice with P5091 inhibits
leukemic tumor growth and prolongs survival of these mice
(Figures 7F and 7G), supporting a broad range of antitumor
activity of P5091 in cancer types. Together, our data demon-
strate that P5091 reduces tumor growth, prolongs survival, and
is well tolerated in vivo.
Combined Treatment with P5091 and Lenalidomide,
Dex, or the HDAC Inhibitor Induces Synergistic Anti-MM
Activity
Our prior preclinical studies (Anderson, 2007) have provided the
basis for clinical trials of bortezomib in combination with lenali-
domide, Dex, and HDAC inhibitors. Given that P5091, like borte-
zomib, targets the UPS, we examined whether P5091 similarly
enhances the anti-MM activity of other agents. Isobogram anal-
ysis (Chou and Talalay, 1984) of synergistic anti-MM activity
demonstrated that the combination of low concentrations of
P5091 and lenalidomide triggers synergistic anti-MM activity
(Figure 8A).
Besides proteasomal degradation, intracellular protein catab-
olism also occurs via an HDAC-dependent aggressome-auto-
phagic cell death-signaling pathway. Recent clinical trials com-
bining bortezomib and HDAC inhibitor vorinostat (SAHA) show
promising outcome in MM. Combination of P5091 and SAHA
triggers synergistic anti-MM activity (Figure 8B). These data
confirm the potential for clinical trials combining USP7 and
HDAC inhibitors. As with lenalidomide and SAHA, the combina-
tion of P5091 with conventional anti-MM agent Dex induces
synergistic anti-MM activity (Figure 8C). Although definitive
evidence of decreased toxicity of combination therapy awaits
results of clinical trials, the synergy observed in vitro may allow
for use of lower doses and decreased toxicity.
Collectively, our studies utilize MM cell lines, patient tumor
cells, and MM xenograft models, as well as biochemical and
genetic models, to show the antitumor activity of a USP7 deubi-
quitylating enzyme inhibitor P5091. The functional specificity of
P5091 is confirmed using different strategies: first, cell-free-(F) Mice bearing CCRF-CEM leukemic tumors were treated with either vehicle or P
as mean tumor volume ± SD (eight mice/group).
(G) Kaplan-Meier survival plot shows survival of mice.
Error bars indicate SD. See also Figure S6.
Canbased experiments using a reporter (Ub-PLA2)-based assay
demonstrate a potent, specific, and selective inhibition of
USP7 activity by P5091; second, P5091 enhances degradation
of its primary substrate HDM2; third, USP7 KO in HCT-116 cells
confers resistance to P5091; and fourth, P5091 blocks USP7
DUB activity without altering proteasome activity. Treatment of
MM cell lines and primary patient MM cells with P5091 inhibits
growth and induces apoptosis in tumor cells, including those
resistant to conventional and bortezomib therapies, without
affecting the viability of normal PBMCs. P5091 triggers apopto-
sis in MM cells, even in the presence of the MM-host BM micro-
environment. Mechanistic studies further show that P5091-trig-
gered apoptosis in MM cells is associated with (1) activation of
caspase-8, caspase-9, caspase-3, and PARP and (2) downregu-
lation of USP7 substrate HDM2, as well as increased expression
of p53 and p21. Genetic studies using siRNA and KO models
show that P5091-induced cytotoxicity is, in part, mediated via
HDM2-p21 and occurs independent of p53. In animal tumor
model studies, P5091 is well tolerated, inhibits tumor growth,
and prolongs survival. Importantly, P5091 inhibits USP7 activity
in vivo and induces apoptosis in MM xenografted tumors. Immu-
nostaining of tumor sections shows that antiangiogenic activity
contributes to the overall antitumor activity of P5091. A side-
by-side efficacy analysis shows a similar antitumor activity of
P5091 and bortezomib at their MTD doses. Finally, combining
P5091 with lenalidomide, HDAC inhibitor, or Dex induces syner-
gistic anti-MM activity. Our preclinical studies therefore provide
the rationale for the development of next-generation UPS-based
therapies and specifically demonstrate the promise of therapeu-
tics targeting USP7 to improve patient outcome in MM.
EXPERIMENTAL PROCEDURES
Cell Lines, MM Patient Cells, and Drug Sources
All studies involving human samples were performed under Dana-Farber
Cancer Institute IRB committee-approved protocols, through which informed
consent was obtained and deidentified samples were utilized. Human MM cell
lines MM.1S, MM.1R, RPMI-8226, U266, KMS12PE, ARP-1, INA-6, Dox-40, or
LR5 were cultured in RPMI-1640 medium containing 10% fetal bovine serum
(FBS) and antibiotics. CCRF-CEM leukemic cells were cultured in 10% FBS
and antibiotics. Human colorectal cancer cell lines HCT116 (WT), HCT116
USP7/, HCT116 p53/, and HCT116 p21/ were maintained in McCoy’s
5A medium with 10% FBS. Tumor cells from MM patients were purified by
CD138+ selection method.
Reagents for In Vitro Enzyme Assays
Recombinant full-length USP5, USP7, and SENP2 catalytic core, as well
as amino terminal-tagged hexa His Ub-PLA2 (Ub-CHOP), Ub-EKL (Ub-
CHOP2), and SUMO3-EKL(SUMO3-CHOP2), were generated, as previously
described (Nicholson et al., 2008; Tian et al., 2011). EKL was generated by
cleaving SUMO3-EKL with SENP2 core, and mature EKL was purified by
affinity chromatography.
Ubiquitin Protease Assays
Recombinant enzymes in 20 mM Tris-HCl (pH 8.0), 2 mM CaCl2, and 2 mM
b-mercaptoethanol were incubated with dose ranges of P5091 for 30 min in
a 96-well plate before the addition of Ub-PLA2 and NBD C6-HPC (Invitrogen,5091 (10mg/kg) twice weekly for three consecutive weeks. Data are presented
cer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier Inc. 355
Figure 8. Combination of P5091 and Lenalidomide, SAHA, or Dex Trigger Synergistic Anti-MM Activity
(A) MM.1S cells were treated for 48 hr with P5091, lenalidomide, or P5091 plus lenalidomide and then assessed for viability using MTT assays. Isobologram
analysis shows the synergistic cytotoxic effect of P5091 and lenalidomide. The graph (right) is derived from the values given in the table (left). The numbers 1–9 in
graph represent combinations shown in the table. FAcom, fraction of viable cells. Combination index (CI) <1 indicates synergy.
(B) MM.1S cells were treated for 48 hr with P5091, SAHA, or P5091 plus SAHA and then assessed for viability usingMTT assays. Synergistic anti-MM activity was
analyzed as in (A).
(C) MM.1S cells were treated for 48 hr with P5091, Dex, or P5091 plus Dex and then assessed for viability using MTT assays. Synergistic anti-MM activity was
analyzed as in (A).
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(Nicholson et al., 2008; Tian et al., 2011). The liberation of a fluorescent product
within the linear range of the assay was monitored using a Perkin Elmer Envi-
sion fluorescence plate reader. Vehicle (2% [v/v] DMSO) and 10 mM N-ethyl-
maleimide (NEM) were included as controls. DUB activity and inhibition assays
in living cells were performed as described (Borodovsky et al., 2002).
Ubiquitin-Linked K48 Chain Cleavage Assay
USP7 (30 nM) was preincubated with DMSO or P5091 for 30 min at room
temperature (RT) before reaction with polyubiquitin chains for 20 min at
37C. Samples were resolved by SDS-PAGE and immunoblotted with anti-
Ub Ab (Sigma Chemicals, St. Louis, MO, USA).
Human Tumor Xenograft Models
All animal experiments were approved by and conformed to the relevant regu-
latory standards of the Institutional Animal Care and Use Committee at the
Dana-Farber Cancer Institute. For the animal study, P5091 was dissolved in
4% NMP (N-methyl-2-Pyrrolidone), 4% Tween-80, and 92% Milli-Q water at
a final concentration of 2 mg/ml. The human plasmacytoma xenograft model
was performed as previously described (Chauhan et al., 2008). CB-17 SCID-
mice (Charles River Labs, Wilmington, MA, USA) were subcutaneously
inoculated with MM.1S, ARP-1, or RPMI-8226 cells in 100 ml of serum-free
RPMI-1640 medium. When tumors were measurable (100–180 mm3), mice
were randomized into treatment groups. In the SCID-hu model, human fetal
bone grafts were subcutaneously implanted into SCID mice. Four weeks after
bone implantation, INA-6 cells were injected directly into the fetal bone implant356 Cancer Cell 22, 345–358, September 11, 2012 ª2012 Elsevier Inin SCID mice; as a measure of tumor burden, mouse sera samples were
analyzed for shIL-6R by ELISA (R&D Systems, Minneapolis, MN, USA). Upon
detection of shIL-6R, mice were treated with vehicle or P5091, and mouse
serum was analyzed for alterations in shIL-6R levels.
Statistical Analysis
Statistical significance in drug-treated versus control in vitro cultures, and in
tumor xenograft models were determined by using the Student’s t test.
Survival of mice was measured by using the Prism GraphPad software (Systat
Software, San Jose, CA, USA). Isobologram analysis (Chou and Talalay, 1984)
was performed using the CalcuSyn software program (Biosoft, Ferguson, MO,
USA; Cambridge, UK). A combination index (CI) less than 1.0 indicates syner-
gistic activity.
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